A groundbreaking moment from 2017— the FDA approval of Kymriah – St. Baldrick’s Foundation

St. Baldrick’s Foundation shared a post on LinkedIn: 

“Today, we’re looking back on a groundbreaking moment from 2017— the FDA approval of Kymriah, the first gene therapy in the U.S. for kids with high-risk leukemia.

This life-saving treatment brought hope to kids like Austin. Diagnosed at 2 with acute lymphoblastic leukemia, Austin faced years of treatment, relapse, and a bone marrow transplant.

By 2013, his cancer had returned, leaving Kymriah as his last hope. Thanks to a St. Baldrick’s-supported clinical trial, Kymriah’s CAR T cells eradicated his cancer.

Now, Austin is 15, cancer-free, and thriving. He’s learning to drive, excelling in trap shooting, and dreaming of becoming a welder.

Kymriah represents hope for kids like Austin, and this hope begins with research — made possible by your support. Help support the next major childhood cancer breakthrough.”

Additional information.
Source: St. Baldrick’s Foundation/LinkedIn